ArticleJournal of general internal medicine2022

The Costs of Delayed Generic Drug Entry: Evidence from a Controversial Prostate Cancer Drug Patent.

David Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.